Cullinan Oncology LLC
$ 12.19
3.04%
10 Feb - close price
- Market Cap 720,140,000 USD
- Current Price $ 12.19
- High / Low $ 12.55 / 11.83
- Stock P/E N/A
- Book Value 7.64
- EPS -3.32
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.40 %
- 52 Week High 13.43
- 52 Week Low 5.68
About
Cullinan Oncology LLC is a leading biopharmaceutical company based in Cambridge, specializing in the development of targeted therapies and immuno-oncology solutions aimed at improving cancer treatment outcomes. The company boasts a robust and diverse pipeline of innovative candidates that address significant unmet medical needs within the oncology sector. With a commitment to groundbreaking research and strategic partnerships, Cullinan is uniquely positioned to make a meaningful impact in the evolving oncology landscape, striving to deliver transformative therapies for patients facing a range of cancers.
Analyst Target Price
$30.39
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-13 | 2025-03-12 | 2024-11-06 | 2024-08-08 | 2024-05-15 | 2024-03-14 | 2023-11-08 | 2023-08-10 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.77 | -1.19 | -0.74 | -0.73 | -0.69 | -0.75 | -0.86 | -0.54 | -0.91 | -0.82 | -1.42 | -0.59 |
| Estimated EPS | -0.95 | -0.82 | -0.99 | -0.7423 | -0.81 | -0.73 | -0.99 | -0.96 | -0.92 | -0.97 | -0.98 | -0.66 |
| Surprise | 0.18 | -0.37 | 0.25 | 0.0123 | 0.12 | -0.02 | 0.13 | 0.42 | 0.01 | 0.15 | -0.44 | 0.07 |
| Surprise Percentage | 18.9474% | -45.122% | 25.2525% | 1.657% | 14.8148% | -2.7397% | 13.1313% | 43.75% | 1.087% | 15.4639% | -44.898% | 10.6061% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.8 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CGEM
2026-02-02 23:28:59
Guggenheim has initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) with a Buy rating and a $30 price target, citing a potential 151% upside. The firm sees this as a good entry point before upcoming Phase 1 data catalysts for the company's T-cell engagers in autoimmune diseases and AML in 2024. Cullinan's strong recent performance, with a 56% price return over the last six months, and the identification of CLN-978 as a primary value driver underpin this positive outlook.
2026-02-02 11:00:15
Guggenheim has initiated coverage on Cullinan Oncology (NASDAQ:CGEM) with a Buy rating and a $30 price target, citing a "good entry point" ahead of anticipated Phase 1 data catalysts for its T-cell engagers. The firm highlights CLN-978 as a primary value driver, expecting data from dose escalations in autoimmune diseases later in 2024. Despite competitive risks, the analyst's outlook is supported by CGEM's recent strong performance and upcoming clinical milestones.
2026-02-02 08:28:25
Guggenheim has initiated coverage on Cullinan Oncology Inc. (NASDAQ:CGEM) with a Buy rating and a $30 price target, predicting a 151% upside. The firm sees this as a good entry point before upcoming Phase 1 data releases for T-cell engagers in autoimmune diseases and AML throughout 2024, with CLN-978 identified as a key value driver. This positive outlook is supported by recent strong performance and other promising clinical developments for the company's therapeutic candidates.
2026-02-01 17:50:00
This article provides a technical analysis of Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting conflicting market sentiment and elevated downside risk. It details AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report suggests choppy market conditions for CGEM based on current signals.
2026-01-24 00:31:27
Jennifer Michaelson, Chief Scientific Officer of Cullinan Oncology (a branch of Cullinan Therapeutics Inc), sold 4,000 shares of CGEM on January 22, 2026. This transaction leaves her with 128,635 shares in the company. Over the past year, Michaelson has sold a total of 15,142 shares, contributing to a total of 11 insider sells against 3 insider buys for Cullinan Therapeutics Inc during the same period.
2026-01-21 16:42:00
This article analyzes Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting its current strong sentiment and potential for a breakout. It provides institutional trading strategies for various risk profiles, including long, momentum breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels. The analysis suggests elevated downside risk due to a lack of additional long-term support signals.
